Zhejiang Starry Pharmaceutical Co (SHSE:603520) Short-Term Debt: ¥1,561 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603520 Zhejiang Starry Pharmaceutical Co Ltd SHSE:603520
76 GF Score
Price ¥8.38
GF Value ¥9.25
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is Zhejiang Starry Pharmaceutical Co Short-Term Debt?

Zhejiang Starry Pharmaceutical Co SHSE:603520 +1.45% 76 Short-Term Debt is ¥1,561 Mil as of Jun. 2026. GuruFocus rates SHSE:603520 with a GF Score™ of 76/100 and a GF Value™ of ¥9.25 (Fairly Valued). The stock has 10 warning signs investors should review.

Zhejiang Starry Pharmaceutical Co's Short-Term Debt for the quarter that ended in Jun. 2026 was ¥1,561 Mil.

Zhejiang Starry Pharmaceutical Co's quarterly Short-Term Debt declined from Dec. 2025 (¥1,884 Mil) to Mar. 2026 (¥1,797 Mil) and declined from Mar. 2026 (¥1,797 Mil) to Jun. 2026 (¥1,561 Mil).

Zhejiang Starry Pharmaceutical Co's annual Short-Term Debt declined from Dec. 2023 (¥2,457 Mil) to Dec. 2024 (¥2,009 Mil) and declined from Dec. 2024 (¥2,009 Mil) to Dec. 2025 (¥1,884 Mil).

Zhejiang Starry Pharmaceutical Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Zhejiang Starry Pharmaceutical Co Short-Term Debt Related Terms

Zhejiang Starry Pharmaceutical Co Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Zhejiang Starry Pharmaceutical Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Starry Pharmaceutical Co Short-Term Debt Chart

Zhejiang Starry Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,457.48 2,311.41 2,456.95 2,009.39 1,884.10

Zhejiang Starry Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,765.18 1,759.01 1,884.10 1,797.03 1,560.97
SHSE:603520
76GF Score
Zhejiang Starry Pharmaceutical Co Ltd SHSE:603520
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ¥1,561 Mil mean?
Zhejiang Starry Pharmaceutical Co (SHSE:603520) has a Short-Term Debt of ¥1,561 Mil as of Jun. 2026.
Is Zhejiang Starry Pharmaceutical Co's Short-Term Debt too high?
Zhejiang Starry Pharmaceutical Co's current Short-Term Debt is ¥1,561 Mil. Overall, Zhejiang Starry Pharmaceutical Co has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Starry Pharmaceutical Co's Short-Term Debt compare to ZTS?
Zhejiang Starry Pharmaceutical Co's Short-Term Debt of ¥1,561 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Zhejiang Starry Pharmaceutical Co's current Short-Term Debt is ¥1,561 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Starry Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Starry Pharmaceutical Co (SHSE:603520) is currently considered Fairly Valued. The stock's GF Value™ is ¥9.25, compared to a current price of ¥8.38 — trading 9.4% below its estimated fair value. The current Short-Term Debt is ¥1,561 Mil. Zhejiang Starry Pharmaceutical Co's overall GF Score™ is 76/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Zhejiang Starry Pharmaceutical Co (SHSE:603520), the current Short-Term Debt is ¥1,561 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhejiang Starry Pharmaceutical Co (SHSE:603520) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Starry Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥8.38 is trading 9.4% below its estimated GF Value™ of ¥9.25. GuruFocus considers Zhejiang Starry Pharmaceutical Co to be Fairly Valued.

Key valuation signals for SHSE:603520:

  • Short-Term Debt: ¥1,561 Mil
  • GF Value™: ¥9.25 vs. price of ¥8.38 (9.4% below fair value)
  • GF Score™: 76/100 with 10 warning signs

No single metric tells the full story. See the SHSE:603520 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zhejiang Starry Pharmaceutical Co Business Description

Address No.1 Sitali Avenue, Modern Industrial Gathering District, Zhejiang Province, Xianju County, Taizhou City, CHN, 317306
Zhejiang Starry Pharmaceutical Co Ltd is engaged in R&D, manufacture and marketing of active ingredient and intermediate X-CT non-ionic contrast agent series and Fluoroquinolones series.
76GF Score

Get the complete analysis for SHSE:603520

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥8.38
Price
¥9.25
GF Value